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Summary 
 The main difficulty in the successful treatment of metastatic melanoma is that this type of cancer is 
known to be resistant to chemotherapy. Chemotherapy remains the treatment of choice and dacarbazine (DTIC) 
is the best standard treatment. The DM-1 compound is a curcumin analog that possesses several curcumin 
characteristics, such as antiproliferative, antitumor and antimetastatic properties. The objective of this study was 
to evaluate the signaling pathways involved in melanoma cell death after treatment with DM-1 compared to the 
standard agent for melanoma treatment, DTIC. 
 Cell death was evaluated by flow cytometry for annexin V and iodide propide (PI), cleaved caspase 8 
and TNF-R1 expression. Hoechst 33342 staining was evaluated by fluorescent microscopy; lipid peroxidation 
(LPO) and cell viability (MTT) were evaluated by colorimetric assays. The antiproliferative effects of the drugs 
were evaluated by flow cytometry for cyclin D1 and Ki67 expression. Mice-bearing B16F10 melanoma were 
treated with DTIC, DM-1 or both therapies. 
  DM-1 induced significant apoptosis as indicated by the presence of cleaved caspase 8 and an increase 
in TNF-R1 expression in melanoma cells. Furthermore, DM-1 had antiproliferative effects in this same cell line. 
DTIC caused cell death primarily by necrosis, and a smaller melanoma cell population underwent apoptosis. 
DTIC induced oxidative stress and several physiological changes in normal melanocytes, whereas DM-1 did not 
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significantly affect the normal cells. DM-1 antitumor therapy in vivo showed tumor burden decrease with DM-1 
monotherapy or in combination with DTIC, besides survival rate increase. 
 Altogether, these data confirm DM-1 as a chemotherapeutic agent with effective tumor control 
properties and a lower incidence of side effects in normal cells compared to DTIC. 
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Introduction 
 
 Metastatic melanoma is characterized by a high mortality rate [1]. This type of skin cancer has 
traditionally been difficult to treat because of its known universal resistance to standard chemotherapy [2]. Early 
stage disease can often be cured by surgery; however, unresectable cancer must be treated with systemic therapy. 
Although a greater percentage of patients are diagnosed with early stage disease compared to previous years, the 
death rate from unresectable melanoma continues to rise [3].  
 Dacarbazine (DTIC) is still considered the standard first-line treatment despite the lack of any evidence 
of this drug improving overall survival [4]. This is because no other single agent or combination of agents have 
demonstrated superiority to DTIC in terms of survival prolongation, even drugs associated with higher response 
rates [5]. Some oncoprotein-targeted drugs are promising as future cancer treatments; however, complete clinical 
responses to these drugs are rare [6].  
 In recent years, some pharmacological approaches have led to new therapy options including immune 
modulators like anti-CTLA4 or BRAF inhibitors like vemurafenib, which showed increased overall survival [7-
8]. On the other hand, these new agents have some limitations and for this reason, classical chemotherapeutic 
drugs still remain in the therapy, especially as combinations of different treatment options aiming have to be 
focused on in order to find better responses in the melanoma treatment. This unsatisfactory treatment outcome 
encourages additional studies on novel therapeutic molecules, delivery systems and combination therapies for 
melanoma [9].  
 Curcumin has long been known as a chemo-preventive and chemotherapeutic agent, and in vivo studies 
with curcumin have demonstrated decreased tumorigenesis in many organs [10], including antiproliferative 
effects in melanoma [11]. Because of its lack of toxicity, there has been increasing interest in further studies with 
curcumin [12,13]. Unfortunately, its poor absorption undermine its clinical potential [14]. 
 DM-1 is a curcumin analog and has previously been studied in animal models, such as melanoma and 
Ehrlich ascites tumor in mice. This compound is a powerful antitumor agent with both antimetastatic and 
antiproliferative activities [15,16]. Its pharmacological activity is restricted primarily to tumor tissue, with 
minimal side effects on the normal surrounding tissue.  
 The objective of this study is to compare the effectiveness of the chemotherapeutic compounds, DTIC 
and DM-1 in melanoma cells, their effects on cell death pathways and their side effects on normal cells. 
 
Materials and methods 
 
Cell lines and culture conditions 
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 The murine melanoma cell line, B16F10, and the human melanoma cell line, A375, were purchased 
from the American Type Culture Collection (Manassas, VA). These cells were grown in 75 cm2 flasks with 
DMEM (Cultilab, SP, Brazil) supplemented with 10% heat-inactivated fetal bovine serum (Cultilab), 2 mM L-
glutamine (Sigma Chemical Company, USA) and 0.1 g/mL streptomycin (FontouraWyeth AS, USA). Primary 
cultures of skin cells (melanocytes) were obtained from the foreskins of University Hospital (Hospital 
Universitário – HU-USP) patients. This project has undergone review and approval by the Ethics Committee of 
HU (HU no. CEP Case 943/09). The melanocytes were maintained in 254CF media (SKU # M-500-254CF; 
Cascade Biologics, USA) supplemented with human melanocyte growth supplement (HMGS – SKU # S-002-5; 
Cascade Biologics) as previously described [17]. The cells were grown at 37 ºC in a 5% CO2 atmosphere.  
 
DM-1: Sodium 4-[5-(4-hydroxy-3-methoxyphenyl)-3-oxo-penta-1,4-dienyl]-2-methoxy-phenolate 
 Dried sodium ethanolate (0.01 mol) was mixed with 1,5-bis(4-hydroxy-3-methoxyphenyl)-1,4-
pentadien-3-one [18] (0.01 mol; 3.26 g) at a 1:1 molar ratio and stirred at room temperature under anhydrous 
reaction conditions followed by solvent rotoevaporation until solidification. The compound C19H17O5Na, has a 
molecular weight of 348 g. Results of the structural characterization of the isolated compound were consistent 
with those described previously by our group [19,20]. 
 
Cell treatment for MTT and LPO assays 
B16F10 melanoma cells, A375 melanoma cells and melanocytes were seeded in 96-well plates at a 
density of 105 cells/mL and allowed to grow for 24 h. They were then treated with different concentrations of 
DTIC (Evolabis, Brazil) or DM-1 diluted in 0.9% NaCl at concentrations ranging from 2560 to 5 µM. As a 
control, the cells were treated with the diluent only. 
 
Cell viability assay (MTT assay) 
After 24 h of treatment with DTIC or DM-1, 10 µM MTT (Sigma Chemical Company, USA) [21] was 
added to each well for an additional 4 h. The blue MTT formazan precipitate was dissolved in 100 µL DMSO. 
The absorbance at 540 nm was measured with a multi-well plate reader. The cell viability was expressed as a 
percentage of the control cells, and the data are shown as the mean value ± s.d. (standard deviation) of three 
independent experiments.  
 
Lipid Peroxidation (LPO) 
The oxidative stress on unsaturated lipids in the cell membranes was evaluated by determining the amount 
of malondialdehyde (MDA), which is the final product of fatty-acid peroxidation. MDA reacts with 
thiobarbituric acid (TBA) to form a colored complex. The thiobarbituric acid reactive substances (TBARS) were 
quantified by spectrophotometric determination (LPO method) [22]. The supernatants from the samples were 
obtained after drug treatment under the same conditions of MTT assay.   
 
Cell treatment for flow cytometry analysis 
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B16F10 cells and melanocytes were seeded in 24-well plates at a density of 105 cells/mL and allowed to 
grow for 24 h. Each cell line was treated with the Inhibitory Concentration 50% (IC50) for each compound for 6 
h.  
 
Mitochondrial membrane electric potential (∆ψm) assessment by flow cytometry 
Rhodamine 123 is a fluorescent cationic dye that binds to polarized mitochondrial membranes and 
accumulates as aggregates in the mitochondria of normal cells [23]. This agent binds only to metabolically active 
mitochondria, resulting in fluorescence emission.  
After treatment, cells in the supernatant and the adherent cells were pelleted by centrifugation at 1800 rpm 
for 10 min and resuspended in 5 µL Rhodamine 123 (5 mg/mL) for 30 min at 37°C. The cells were then washed 
with phosphate-buffered saline (PBS) and resuspended in FACS buffer (FACSCalibur-Becton Dickinson, USA). 
The samples were analyzed for fluorescence using a FL-1H detector on a Becton Dickinson FACScan flow 
cytometer using the CellQuest software. Flow cytometry histograms were recorded, and the relative intensity of 
fluorescence was calculated as the mean of active mitochondria (viable cells) or inactive mitochondria (inviable 
cells) of the control and treated samples. 
 
Apoptosis analysis by flow cytometry 
Annexin V staining detects the translocation of phosphatidylserine from the inner to the outer cell 
membrane during early apoptosis, and propidium iodide (PI) can enter the cell during late-stage apoptosis and 
also stains dead cells [23]. 
After treatment, the cells in the supernatant and the adherent cells were washed with PBS and binding 
buffer (10 mM HEPES pH 7.5 containing 140 mM NaCl and 2.5 mM CaCl2) and stained with 1 µg annexin V-
FITC (Santa Cruz Biotechnology, USA) and 18 µg/mL of propidium iodide (Sigma-Aldrich Corp.). Each sample 
was analyzed by flow cytometry using the FL-1 and FL-2 channels to distinguish the apoptotic, necrotic, and 
viable cell populations. The analysis was performed on a FACSCalibur flow cytometer using the CellQuest 
software (FACSCalibur; Becton Dickinson). 
 
Protein analysis by flow cytometry 
After treatment, the cells in the supernatant and the adherent cells were pelleted by centrifugation at 1800 
rpm for 10 min and incubated with 1 µg of specific anti-cyclin D1 (Santa Cruz, USA), anti-Ki67 (Dako, USA), 
anti-caspase 8 or anti-TNF-R1 receptor
 
antibodies (tumor necrosis factor-α receptor) (Santa Cruz, USA) and 10 
µL 0.1% Triton X-100 for 1 h at 4°C. Then, the samples received addition of 2 µL anti rabbit IgG-Alexafluor-
488 (Invitrogen, USA) in untagged primary antibody coupled cells and incubated further in dark for 30–35 min. 
Excess fluorescence was then washed off with PBS. Subsequently, the cells were resuspended in FACS buffer. 
The samples were analyzed for fluorescence (FL-1 channel) on a Becton Dickinson FACScan flow cytometer 
using the Cell Quest software. 
 
Hoechst staining 
 Cell nuclear morphology was evaluated by fluorescence microscopy following Hoechst 33342 DNA 
staining (Sigma–Aldrich Corp). A375 human melanoma cells were seeded in 24-well plates at a density of 105 
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cells/mL and were grown for 24 h. This cell line was treated with the IC50 for either DTIC or DM-1 alone or a 
combination of 5 µM DTIC + 5 µM DM-1 for 24 h. These concentrations were chosen in order to verify if the 
addition of DM-1 compound would allow the DTIC concentration decrease down to 10% of IC50 with the same 
efficacy in this cell type. The cells were washed with phosphate buffer saline (PBS), resuspended in 2 µg/mL 
Hoechst 33342 and incubated for 30 min at 37ºC in the dark. Then, cells were then washed with PBS and 
examined under a Nikon fluorescent microscope. 
 
Inoculation of B16 melanoma cells in mice 
The murine B16F10 was cultivated in RPMI-1640 medium supplemented with 10 % fetal bovine serum 
(FBS), 2 mM-Lglutamine, 1 mM sodium pyruvate and 100 IU/ml of penicillin and 100 µg/ml of streptomycin 
(Invitrogen Inc, Carlsbad, USA). Cell suspensions were detached from plates with trypsin. After trypsin 
inactivation with 10% FBS, viable cells were counted by trypan blue dye exclusion. For tumor inoculation, 
5×104 cells were suspended in 100 µl of PBS and injected subcutaneously into the flank regions of C57BL/6J 
mice. Ten to fourteen days after inoculation the tumors became macroscopically apparent. 
 
In vivo antitumor activity 
 Mice were inoculated with B16F10 melanoma cells as described above and were randomly allocated to 
four groups of 5 animals. The DM-1 compound and DTIC were administered by intraperitoneal way. The DM-1 
compound was administered daily and its concentration was 83 µM in 100 µL of saline solution. This 
concentration was calculated considering the IC50 value determined in the in vitro assay. 
 On fourteen day counted from the initial inoculation day, four experimentation groups were used: 
Control: five mice-bearing B16F10 melanoma were treated with 100 µL of saline solution 0.9%; 
DTIC: five mice-bearing B16F10 melanoma were treated with 4.5 mg/kg/body mass of DTIC [24] diluted in 
saline solution 0.9% every two days for a total of seven doses; 
DM-1: five mice-bearing B16F10 melanoma were treated daily with DM-1 compound diluted in saline solution 
0.9%; 
DTIC+DM-1: five mice-bearing B16F10 melanoma were treated daily with DM-1 compound diluted in saline 
solution 0.9% plus 4.5 mg/kg/body mass of DTIC every two days for a total of seven doses; 
 Tumor sizes were measured daily using a calipers-like instrument. The size measurement was converted 
to tumor volume by the equation: tumor area= ΠR2, where Π was (length tumor + width tumor)/4 [25]. 
Necropsies were performed after 14 days of tumor inoculation. All animal experiments were carried out 
according to the regulations of the Ethical Committee for Animal Research at the Butantan Institute (479/09). 
 
Statistical analysis 
 The values are expressed as the mean ± s.d. The data were analyzed using a one-way analysis of 
variance (ANOVA). Significant differences in the means were determined using multiple comparisons with the 
Tukey-Kramer test at a significance level of p<0.05. Any significant differences between the control and treated 
groups are indicated as ***p<0.001, **p<0.01, and *p<0.05.  
 
Results 
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DM-1 decreases cell viability in melanoma cells 
 To evaluate the cytotoxic effects of DM-1 and DTIC, B16F10 murine melanoma cells, A375 human 
melanoma cells and normal melanocytes were treated with different drug concentrations for 24 h and cell 
viability was determined by MTT assay. 
 Consistent with the results of Henmi and co-workers [26], the chemotherapeutic agent DTIC, had high 
IC50 values in the A375 human melanoma cell line. For the B16F10 murine melanoma cells, this value was even 
higher. DM-1 had greater cytotoxic effects that were approximately 46- and 8-fold higher in the murine and 
human melanoma cell lines, respectively, compared to DTIC. Treatment of the normal melanocytes showed no 
significant differences between the IC50 values of the two compounds (Table 1). Altogether, these results 
indicate that DM-1 has a higher potency and selectivity for cancer cells, whereas DTIC acts similarly in both 
cancer and normal cells. 
 
Please insert Table 1 here. 
 
DM-1 induces cell death by apoptosis in melanoma cells 
   
 As observed above, DTIC and DM-1 treatment of B16F10 cells induced a significant decrease in cell 
viability. To discriminate the type of cell death triggered by these drugs, annexin V flow cytometry analysis was 
performed. Four different populations of cells were easily identified: unlabeled viable cells, annexin V positive 
cells (early apoptotic), PI positive cells (necrotic) and annexin V and PI positive cells (late apoptotic).  
 In our experiments, DTIC treatment increased the percentage of necrotic B16F10 cells by 
approximately 75%. Conversely, DM-1 significantly increased the percentage of cells undergoing late apoptosis, 
to approximately 90% after 6 h of treatment (Fig. 1 A-D). In normal melanocytes, these two types of cell death 
were not significantly changed with either treatment (Fig. 1 E-H). 
 
Please insert Figure 1 here. 
 
Mitochondrial membrane potential (∆ψm) changes are an additional indication of apoptosis because ∆ψm 
contributes to the process that facilitates the exit of many apoptogenic factors to the cytosol. As shown in fig. 2 
(A-C), the electric mitochondrial membrane potential of B16F10 melanoma cells was decreased after 6 h of 
treatment with DTIC and DM-1. Both treatments induced a significant reduction in ∆ψm; however, DM-1 
caused a 65% decrease in viable cells and/or active mitochondria, whereas DTIC induced only a 12% decrease in 
viable cells and/or active mitochondria compared to the untreated cells. 
 Melanocytes treated with DTIC showed a moderate decrease in mitochondrial electric potential. In 
addition, DM-1 treatment did not change this potential in normal cells (Fig. 2 D-F), demonstrating DM-1 
specificity for cancer cells. 
 
Please insert Figure 2 here. 
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 Finally, nuclear morphological changes were examined because they are another classical feature of 
apoptosis. The cells were examined under fluorescence microscopy after Hoechst 33342 staining to confirm 
apoptotic cell death. The apoptotic nuclei were distinctively marginated and fragmented when observed under 
the fluorescent microscope. 
 The control cells were highly confluent and displayed regular nuclear structure (Fig. 3 A). After DTIC 
treatment (IC50), a few of the A375 human melanoma cells showed ‘bean-shaped’ nuclei (Fig. 3 B). DM-1 
treatment (IC50) induced the formation of apoptotic bodies and nuclear condensation (Fig. 3 C). 
 The combination of DTIC and DM-1, each at lower concentrations (5 µM), induced the formation of 
apoptotic bodies, 'bean-shaped’ nuclei, highly condensed chromatin and nuclei with irregular clumps of dense 
chromatin (Fig. 3 D). These results suggest a synergistic effect between DTIC and DM-1. 
 
Please insert Figure 3 here. 
 
Extrinsic apoptotic pathway activation 
Apoptosis can be induced by the extrinsic and/or the intrinsic (mitochondrial) pathway. Caspases represent a 
family of cysteine proteases that are common downstream effectors of apoptosis. The cleavage of caspase 8 
indicates cell death initiated by the extrinsic apoptotic pathway [27]. The expression levels of several markers of 
this pathway, such as cleaved caspase 8 and TNF-R1, were evaluated after 6 h of DTIC or DM-1 treatment. Both 
treatments caused an increase of cleaved caspase 8 in the B16F10 melanoma cells; however, only DM-1 
increased TNF-R1 levels (Fig 4 A and C). Notably, there was a moderate decrease in the level of cleaved caspase 
8 in the melanocytes, but changes in the TNF-R1 were not observed. This indicates that the extrinsic apoptotic 
pathway is not activated in the normal melanocytes (Fig. 4 B and D). 
 
Please insert Figure 4 here. 
 
Free radical production 
 Oxidative stress causes cellular damage, which can lead to apoptosis. To evaluate whether DTIC and 
DM-1 induce oxidative stress in melanoma cells, free radical production was assessed by the evaluation of 
malondialdehyde production in the cytoplasmic membranes of B16F10 melanoma cells and melanocytes after 
drug treatment. 
 DTIC induced an approximately 10-fold increase in the amount of malondialdehyde in the B16F10 
cells. Significant effects were observed until a concentration of 160 µM (Fig. 5 A). By contrast, DTIC caused a 
doubling of malondialdehyde synthesis in normal melanocytes and a significant damage was observed with the 
majority of concentrations tested, up to 80 µM (Fig. 5 B).  
 DM-1 treatment increased the malondialdehyde concentration by 130-fold in the B16F10 melanoma 
cell line and induced damage at all the concentrations tested (Fig. 5 C). Furthermore, DM-1 caused less damage 
than DTIC at the same concentrations in normal melanocytes. A moderate increase of malondialdehyde 
production was observed only for the two highest concentrations tested (Fig. 5 D). 
 
Please insert Figure 5 here. 
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DM-1 and DTIC have antiproliferative effects on melanoma cells, but not normal cells 
 The antiproliferative effects of the drugs on the melanoma cells were evaluated by cyclin D1 and Ki67 
protein expression. Type D cyclins, together with their CDK partners, form a key regulatory unit of the G1/S 
transition that is frequently impaired in neoplasia [28]. The Ki67 nuclear protein is expressed in proliferating 
cells and may be necessary to maintain cell proliferation. Ki67 has been used as a marker of cell proliferation in 
solid tumors [29].  
 Cyclin D1 levels were significantly decreased after DTIC (p<0.01) and DM-1 (p<0.001) treatment in 
B16F10 melanoma cells (Fig. 6 A). Conversely, this reduction was not observed in the normal melanocytes. In 
fact, these cells presented a slight increase in the expression of cyclin D1 after treatment (Fig. 6 B).  
 By contrast, Ki67 expression was significantly decreased after treatment of the melanoma cells with 
DTIC or DM-1, (Fig. 6 C). DM-1 did not modify expression of Ki67 in normal melanocytes; however, a 
moderate increase in expression of this marker was observed after DTIC treatment (Fig. 6 D).  
 
Please insert Figure 6 here. 
 
In vivo DM-1 antitumor effect 
 The DM-1 compound also showed in vivo antitumor activity. The cytotoxic effects were obtained with 
DM-1 compound administration alone or in combination with chemotherapeutic DTIC. The B16F10 melanoma-
bearing mice without treatment (control group) showed a significant tumor area increase. The group receiving 
DTIC chemotherapy alone showed a 43% tumor burden decrease in comparison to the control group. The group 
treated with DM-1 compound alone and the group treated with both therapies showed 57% and 63% tumor 
burden reduction, respectively, compared to control group (Figure 7A). Both groups treated with DM-1 
compound showed better antitumor effects than DTIC monotherapy. 
 After 28 days of B16F10 melanoma cell inoculation, there were no live animals in the control group. In 
this same period, there were 40% of live mice treated with DTIC in monotherapy. The mice survival rate of both 
DM-1 groups (monotherapy or in combination with DTIC) was significantly increased in comparison to the 
control group or DTIC monotherapy, because in the end of 14 treatment days with DM-1, all mice remained 
alive (Figure 7B). 
 
Please insert Figure 7 here. 
 
Discussion 
  
 The incidence of melanoma continues to rise, and an estimated increase of 27% in new diagnoses was 
made in 2012. This is significantly greater than only 5 years ago [3]. This increase in incidence is due both to 
improved awareness leading to additional diagnoses and to life style changes that have resulted in an increase in 
sun exposure over the past decades. Moreover, melanoma has a known resistance to chemotherapy and this is 
related, in part, to defects in proapoptotic signaling [30]. 
 The DM-1 compound showed IC50 values considerably lower than the currently used chemotherapeutic, 
DTIC. In addition, it induced injury to tumor cells at lower concentrations, and also caused oxidative damage in 
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the B16F10 melanoma cell line at all concentrations tested (2560-5 µM). DTIC showed similar levels of damage 
in only half the concentrations tested, and had less cytotoxic potential than DM-1. Furthermore, DTIC caused 
oxidative damage in the normal melanocytes at the same concentrations used for treating the melanoma cells. 
DM-1 caused oxidative damage only in the melanocytes treated with the two highest concentrations of drug. 
Pretreatment with different concentrations of another curcumin analog caused a significant decrease in the levels 
of TBARS and DNA damage in normal hepatocytes [31]. 
 Reactive oxygen species (ROS) interact with biological molecules to produce toxic free radicals 
resulting in lipid peroxidation (LPO) and DNA damage [32]. Furthermore, LPO products, such as 
malondialdehyde, form adducts with cellular DNA. LPO can be defined as a cascade of biochemical events 
resulting from the action of free radicals on the unsaturated lipids of cell membranes. This generates primarily 
alkyl, peroxyl and alkoxyl radicals, leading to destruction of their structure, the failure of mechanisms that 
exchange metabolites and cell death. Therefore, LPO can be used as an indicator of cellular oxidative stress [33]. 
 In non-apoptotic cells, most phosphatidylserine molecules are localized to the inner layer of the plasma 
membrane. However, in the annexin V assay, the translocation of phosphatidylserine residues from the internal 
layer to the outer face of the plasma membrane prior to the loss of membrane integrity is an indicator of 
apoptotic induction [23]. After DM-1 treatment, the majority of the B16F10 melanoma cells showed cell death 
by apoptosis, whereas cells treated with DTIC presented necrosis as the main type of cell death. In melanocytes, 
these effects were not observed.  
 Disruption of the ∆ψm is an early event associated with apoptosis and has been suggested to be one of 
several factors responsible for cytochrome c release [34]. Melanoma cells showed a significant decrease in the 
∆ψm for both treatments. However, DTIC also caused this effect in normal melanocytes, thereby inducing 
changes in cell polarity and causing cell death.  
 Extrinsic and intrinsic apoptotic pathways have both been described [35]. The extrinsic pathway is 
initiated by binding of TNF-R1, CD95L/FasL or TRAIL to death receptors, the formation of death-inducing 
signaling complexes (DISC) and activation of the initiator caspases 8 and 10 [36]. By contrast, the intrinsic 
pathway is initiated by cellular and DNA damage and utilizes mitochondria particularly. Key events that occur 
when the intrinsic apoptotic pathway is activated are the depolarization of ∆ψm and mitochondrial outer 
membrane permeabilization (MOMP). This results in the release of mitochondrial factors, such as cytochrome c, 
AIF (apoptosis-inducing factor) and SMAC (second mitochondria derived activator of caspases) [37]. The 
initiator caspases 8, 9 and 10 activate the downstream effector caspases 3, 6 and 7, which cleave a large number 
of death substrates to initiate apoptosis [38]. 
 DM-1 treatment induced an increase in TNF-R1 expression, in addition to significant activation of 
caspase 8. DTIC also induced moderate caspase 8 cleavage; however, there was no increase in TNF-R1 
expression. Bill and coworkers also showed that a curcumin analog induced apoptosis through caspase 8 
cleavage after 24 h of treatment. This compound also resulted in the loss of mitochondrial membrane potential in 
the melanoma cells [39].  
 Additionally, the morphological changes in the A375 human melanoma cells treated with DM-1 
included the formation of apoptotic bodies and condensed chromatin, whereas the cells treated with DTIC 
presented with ‘bean-shaped’ nuclei when analyzed by Hoechst 33342 staining. However, the combination of 
both treatments, at appreciably lower concentrations, induced all of the above cited characteristics. It is known 
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that the effects of DTIC can be improved by combination with other chemotherapeutic agents or new compounds 
[40]. Together with the annexin V data, it can be concluded that only a small population of cells treated with 
DTIC undergo apoptosis, whereas the majority die by necrosis. However, the results obtained with DM-1 
indicate that DM-1 induces apoptosis in melanoma cells.  
 Cell cycle dysregulation is a fundamental process in tumor progression, and unregulated cell 
proliferation is a feature of malignant tumors. Cell proliferation and the cell cycle are regulated by the formation, 
activation, and degradation of a series of cyclins and cyclin-dependent kinase complexes. Cyclin D1, a G1 cell-
cycle protein, phosphorylates and inactivates the tumor-suppressor protein, retinoblastoma, and promotes the 
progression from G1 to S phase [41]. Increased proliferative activity of tumor cells is also associated with 
malignancy and is an important prognostic marker in many human cancers. Markers that are widely used to 
assess cell proliferation are the proliferating cell nuclear antigen and the Ki67 protein. The latter is a nuclear 
antigen synthesized throughout most of the cell cycle, except during the G0 and early G1 phases [42]. 
 Cyclin D1 expression in melanoma cells was reduced after treatment with both DTIC and DM-1. This 
effect was the opposite of what was observed in the normal melanocytes. This could be explained as a 
proliferative response to injury caused by the treatments. These effects were partially observed for Ki67 
expression. The melanoma cells had reduced expression of Ki67, whereas the melanocytes treated with DTIC 
showed a moderate increase in Ki67 expression. There were no significant changes in Ki67 expression in 
melanocytes treated with DM-1. Curcumin and some of its analogs also induce a decrease in cyclin D1 
expression [43]. This way, the analogs, including DM-1, can be effective in regulating the cell cycle progression 
of tumor cells. 
 As action mechanism, the DM-1 compound induces cell cycle arrest by cyclin D1 and Ki67 decrease 
and apoptosis by free radicals production, TNF-R1 and cleaved caspase-8 increase, as well mitochondrial 
electrical potential decrease. Furthermore, apoptosis was also confirmed by apoptotic bodies in human 
melanoma cell line. That is, the extrinsic and intrinsic apoptosis pathways were enabled by DM-1. DM-1 
compound also induces Bcl-2 and Mcl-1 decrease, besides caspase 3, 9 and Parp cleavage (data not shown). 
DM-1 antitumor therapy in vivo showed tumor burden decrease with DM-1 monotherapy or in combination with 
DTIC, besides survival rate increase. Aggarwal and coworkers showed a decrease of approximately 30% in 
tumor burden after treatment with curcumin analogs, while our study found an approximately 60% of reduction 
[44]. Tumor burden decrease and survival rate increase were also found in mice-bearing breast cancer after DM-
1 treatment in combination with paclitaxel chemotherapeutic [15].  
 In conclusion, the molecular and cellular mechanisms related to tumor cell death after DM-1 treatment 
compared to the currently used chemotherapeutic agent, DTIC, have been presented. Here, we confirm the high 
toxicity and nonspecificity of DTIC when used for tumor treatment. Moreover, these results show that DM-1 
induces tumor cell apoptosis through both the extrinsic and intrinsic pathways, and DM-1 treatment also causes 
cell cycle arrest. In vivo antitumor therapy showed high synergism between DTIC and DM-1 may help side 
effects decrease during melanoma treatment. These data confirm DM-1 as a powerful chemotherapeutic agent 
with effective tumor control properties and a lower incidence of side effects in normal cells compared to DTIC. 
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Legends 
 
Figure 1 – Representative histograms of B16F10 melanoma cells (A) control, (B) DTIC, (C) DM-1 and 
melanocytes (E) control, (F) DTIC, (G) DM-1 stained with annexin-V (FL-1H axis X) and propidium iodide 
(FL-2H axis Y) for cell death quantification. The distribution (mean±s.d.) is the number of viable, necrotic and 
apoptotic (D) B16F10 melanoma cells and (G) melanocytes.  
ns: not significant compared to the control. 
*p<0.05 and ***p<0.001 compared to control. 
 
Figure 2 – Representative overlaps of fluorescence intensity from melanoma cells and normal melanocytes 
stained with Rhodamine 123 and analyzed by flow cytometry. The overlaps represent the B16F10 melanoma 
cells treated with (A) DTIC and (B) DM-1 and the melanocytes treated with (D) DTIC and (E) DM-1. The 
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distribution (mean±s.d.) is the number of (C) B16F10 melanoma cells and (F) melanocytes with active 
mitochondria (viable cells) or inactive mitochondria (inviable cells).  
ns: not significant compared to the control. 
*p<0.05 and ***p<0.001 compared to the control. 
 
Figure 3 – Detection of apoptotic cells by Hoechst 33342 staining. A375 human melanoma cells (A) control and 
treated for 24 h with (B) DTIC (IC50 – 548 µM), (C) DM-1 (IC50 – 65 µM) or (D) a combination of DTIC (5 
µM) + DM-1 (5 µM) (400x magnification). The inset represents the cell confluence (100x magnification). 
 
Figure 4 - Expression of apoptotic markers in melanoma cells and normal melanocytes (normalized values of the 
mean ± s.d.) by flow cytometry. Cleaved caspase 8 expression after DTIC and DM-1 treatment compared to the 
control in (A) B16F10 melanoma cells and (B) melanocytes. TNF-R1 expression after DTIC and DM-1 
treatment compared to the control in (C) B16F10 melanoma cells and (D) melanocytes.  
ns: not significant compared to the control. 
*p<0.05, **p<0.01, and ***p<0.001 compared to the control. 
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Figure 5 - Malondialdehyde production after DTIC (A) and DM-1 (B) treatment in B16F10 melanoma cells, and 
(C) DTIC and (D) DM-1 treatment in melanocytes at different concentrations compared to the control.  
ns: not significant compared to the control. 
**p<0.01 and ***p<0.001 compared to the control. 
 
Figure 6 - Expression of cell cycle regulator markers in melanoma cells and normal melanocytes (normalized 
values of the mean ± s.d.) by flow cytometry. Cyclin D1 expression after DTIC and DM-1 treatment compared 
to the control in (A) B16F10 melanoma cells and (B) melanocytes. Ki67 expression after DTIC and DM-1 
treatment compared to the control in (C) B16F10 melanoma cells and (D) melanocytes. 
ns: not significant compared to the control. 
**p<0.01, and ***p<0.001 compared to the control. 
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Figure 7 - Tumor growth of mice bearing B16F10 melanoma after DTIC, DM-1 or DTIC+DM-1 treatment in 
comparison to control group. (A) Tumor area measurements were obtained subsequent to the 14th day of tumor 
inoculation during 14 treatment days. The tumor burden is represented next to each respective treatment line. 
The values are expressed as mean ± s.d.; (B) Survival rate of mice bearing B16F10 melanoma subsequent to the 
14th day of tumor inoculation during 14 treatment days.  Significance is indicated by: ***p<0.001 compared to 
control; &p<0.05 to compare DTIC+DM-1 and DM-1 groups; ###p<0.001 to compare DTIC+DM-1 and DTIC 
groups. 
